Brokerages Expect Omnicell, Inc. (OMCL) Will Announce Quarterly Sales of $213.18 Million

Equities analysts predict that Omnicell, Inc. (NASDAQ:OMCL) will post sales of $213.18 million for the current quarter, according to Zacks. Three analysts have made estimates for Omnicell’s earnings. The lowest sales estimate is $210.97 million and the highest is $214.56 million. Omnicell reported sales of $188.67 million in the same quarter last year, which indicates a positive year over year growth rate of 13%. The company is scheduled to announce its next quarterly earnings report on Thursday, July 25th.

On average, analysts expect that Omnicell will report full year sales of $891.93 million for the current year, with estimates ranging from $889.57 million to $895.01 million. For the next financial year, analysts forecast that the business will post sales of $968.62 million, with estimates ranging from $934.29 million to $990.26 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for Omnicell.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, April 25th. The company reported $0.61 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.23 by $0.38. The company had revenue of $202.50 million for the quarter, compared to analysts’ expectations of $199.72 million. Omnicell had a return on equity of 11.10% and a net margin of 4.74%. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.29 earnings per share.

A number of equities research analysts have recently weighed in on the company. Benchmark lifted their price target on Omnicell from $82.00 to $90.00 and gave the company a “buy” rating in a report on Friday, April 26th. BidaskClub raised Omnicell from a “hold” rating to a “buy” rating in a report on Wednesday, February 13th. ValuEngine raised Omnicell from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Zacks Investment Research cut Omnicell from a “hold” rating to a “sell” rating in a report on Friday, February 15th. Finally, Dougherty & Co boosted their target price on Omnicell from $78.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, March 7th. Five research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Omnicell currently has a consensus rating of “Buy” and an average target price of $79.89.

Shares of OMCL traded down $0.50 during mid-day trading on Friday, reaching $81.79. 249,922 shares of the company’s stock traded hands, compared to its average volume of 345,550. The stock has a market cap of $3.39 billion, a PE ratio of 53.19, a price-to-earnings-growth ratio of 2.69 and a beta of 1.20. The company has a current ratio of 1.96, a quick ratio of 1.47 and a debt-to-equity ratio of 0.13. Omnicell has a 12 month low of $45.15 and a 12 month high of $86.87.

In other Omnicell news, insider Peter J. Kuipers sold 13,000 shares of Omnicell stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $81.62, for a total value of $1,061,060.00. Following the transaction, the insider now owns 55,829 shares in the company, valued at $4,556,762.98. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Gary S. Petersmeyer sold 750 shares of Omnicell stock in a transaction that occurred on Tuesday, February 12th. The stock was sold at an average price of $78.87, for a total transaction of $59,152.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 188,916 shares of company stock worth $14,362,850. 2.77% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of OMCL. Bank of New York Mellon Corp grew its position in shares of Omnicell by 2.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 946,239 shares of the company’s stock valued at $68,035,000 after acquiring an additional 22,890 shares during the period. Advisors Asset Management Inc. raised its holdings in shares of Omnicell by 145.4% during the 3rd quarter. Advisors Asset Management Inc. now owns 4,328 shares of the company’s stock worth $311,000 after acquiring an additional 2,564 shares in the last quarter. Teachers Advisors LLC raised its holdings in shares of Omnicell by 2.2% during the 3rd quarter. Teachers Advisors LLC now owns 99,805 shares of the company’s stock worth $7,176,000 after acquiring an additional 2,159 shares in the last quarter. Legal & General Group Plc raised its holdings in Omnicell by 10.6% during the 3rd quarter. Legal & General Group Plc now owns 92,226 shares of the company’s stock valued at $6,632,000 after buying an additional 8,836 shares during the period. Finally, Vanguard Group Inc. raised its holdings in Omnicell by 27.9% during the 3rd quarter. Vanguard Group Inc. now owns 3,806,211 shares of the company’s stock valued at $273,665,000 after buying an additional 830,338 shares during the period. Hedge funds and other institutional investors own 95.55% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

See Also: Stock Ratings and Recommendations: Understanding Analyst Upgrades and Downgrades

Get a free copy of the Zacks research report on Omnicell (OMCL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.